Merck 2014 Annual Report Download - page 103
Download and view the complete annual report
Please find page 103 of the 2014 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93 -
94 -
95 -
96 -
97 -
98 -
99 -
100 -
101 -
102 -
103 -
104 -
105 -
106 -
107 -
108 -
109 -
110 -
111 -
112 -
113 -
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
-
181
-
182
-
183
-
184
-
185
-
186
-
187
-
188
-
189
-
190
-
191
-
192
-
193
-
194
-
195
-
196
-
197
-
198
-
199
-
200
-
201
-
202
-
203
-
204
-
205
-
206
-
207
-
208
-
209
-
210
-
211
-
212
-
213
-
214
-
215
-
216
-
217
-
218
-
219
-
220
-
221
-
222
-
223
-
224
-
225
-
226
-
227
-
228
-
229
-
230
-
231
-
232
-
233
-
234
-
235
-
236
-
237
-
238
-
239
-
240
-
241
-
242
-
243
-
244
-
245
-
246
-
247
-
248
-
249
-
250
-
251
-
252
-
253
-
254
-
255
-
256
-
257
-
258
-
259
-
260
-
261
-
262
-
263
-
264
-
265
-
266
-
267
-
268
-
269
-
270
-
271
 |
 |
98 GROUP MANAGEMENT REPORT → REPORT ON ECONOMIC POSITION → Biopharmaceuticals
%
Europe → 2,424.3
North America → 1,291.9
Emerging Markets → 1,666.9
Rest of World → 400.2
22
29
7
42
BIOPHARMACEUTICALS →
SALES BY REGION – 2014
€ million / % of divisional sales
Europe, the division’s top-selling region, posted a slight organic
sales decline of –1.4 % and a negative foreign exchange impact of
– 0.3 %, thereby generating sales of €2,424 million (2013: €2,467
million). The share of divisional sales accounted for by Europe
declined to 42 % (2013: 43 %). Some western European countries
recorded a decline in sales.
At 13.5 %, the strongest organic growth was achieved in
Emerging Markets, the division’s second-largest region in terms of
sales. Consequently, the share of sales generated by the Emerging
Markets region increased by two percentage points to 29 %, there-
by demonstrating the growing importance of this region. All fran-
chises contributed to the organic sales growth of the division. The
main drivers were Erbitux®, Gonal-f® (treatment of infertility) and
medications to treat cardiovascular diseases and thyroid disorders.
Taking negative currency effects of – 5.3 % into account, sales rose
by a total of 8.2 % to €1,667 million (2013: €1,540 million).
Sales in North America amounted to € 1,292 million in 2014,
which was slightly more than the previous year (2013: € 1,280
million). Rebif® and the Fertility franchise were primarily respon-
sible for the organic sales increase of 1.0 %. Unfavorable foreign
exchange effects were responsible for a decline of – 0.1 %. The
North America region contributed 22 % to the division’s sales
(2013: 23 %).
In the Rest of World region, sales grew organically by 5.2 %,
mainly powered by the good sales performance of Erbitux® and
strong demand for products from the Fertility franchise. Including
negative exchange rate effects of – 5.6 %, which were primarily
attributable to the Japanese yen, sales totaled €400million (2013:
€402 million). Once again, the Rest of World region contributed
7 % to divisional sales.